Illumina MiSeq i100Plus sequencing system

The Food and Drug Administration is procuring an Illumina MiSeq i100Plus sequencing system to support the FDA Chief Scientist Challenge Grant, which focuses on developing novel sequencing applications to improve the safety of critical foods such as powdered infant formula. The desktop genomic sequencer must meet stringent performance requirements including high accuracy exceeding 99.9999% consensus, scalability with 3-300 GB output per run, fast runtime of approximately 15 hours, and cost-efficiency delivering a 66% reduction in sequencing cost per sample. The procurement is designated under NAICS code 334516 for Analytical Laboratory Instrument Manufacturing with a small business size standard of 1000 employees. The government will evaluate quotations using lowest-price technically acceptable criteria, with technical and price factors weighted approximately equally. Questions must be submitted by September 8, 2025, with quotations due on the same date as specified in the SAM.gov posting.

This is an unrestricted procurement with no set-aside designations, making it open to all qualified contractors regardless of size or socioeconomic status. The contract will be awarded as a firm-fixed-price arrangement for the desktop genomic sequencer with enhanced performance and modern chemistry capabilities. Delivery and installation must be completed within 15-30 days of contract award at the CPK1 Building located at 9591 Baltimore Ave, College Park, Maryland 20740. The solicitation documents identify this as RFQ number 75F40125Q00331, though specific contract values or budget ranges are not disclosed in the available documentation. The system will support a wide array of genomic applications beyond the primary objective of food safety research.